Alzheimer’s: Starting the impossible journey
Not long ago, the prospect of having disease-modifying treatments for Alzheimer’s disease (AD) seemed almost a flight of fancy.
Newsletters and Deep Dive digital magazine
Not long ago, the prospect of having disease-modifying treatments for Alzheimer’s disease (AD) seemed almost a flight of fancy.
As the EASD congress draws to a close, here's a round-up of some of the other clinical trials in diabetes and obesity that drew our attention.
Varda has closed a $251m round to fuel its mission to make medicines in orbit, with TriGemX, Breye, AnaCardio, and ai3Bio also raising new funds.
Shai Melcer discusses bioconvergence, a multidisciplinary research and development approach that merges technologies.
Bayer has looked internally for its chief medical officer, appointing Christoph Koenen to the post alongside his current clinical development role.
Editor's Picks
Newsletters and Deep Dive
digital magazine